Xtant Medical Holdings (XTNT) Tops Q2 EPS by 3c, raises guidance

Xtant Medical Holdings (NYSE: XTNT) reported Q2 EPS of $0.02, $0.03 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.35 million.

GUIDANCE:

Xtant Medical Holdings sees FY2025 revenue of $131-135 million, versus the consensus of $129.6 million, which represents approximately 11% to 15% growth over the Company\'s 2024 revenue. This compares to its prior revenue guidance of $127 million to $131 million. Xtant intends to update its outlook following the completion of the sale of its non-core Coflex® and CoFix® spinal implants and all OUS businesses to Companion Spine.

For earnings history and earnings-related data on Xtant Medical Holdings (XTNT) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c